If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPMO.L Regulatory News (PMO)

  • There is currently no data for PMO

Lender Discussions Update

1 Jul 2016 07:00

RNS Number : 8772C
Premier Oil PLC
01 July 2016
 

PREMIER OIL PLC

("Premier" or "the Company")

Lender discussions update

01 July 2016

 

As previously announced, Premier is in discussions with its lending group on the terms of its existing financial facilities. These are progressing well.

The lending group has agreed that the test of Premier's financial covenants at 30 June 2016 will be waived and replaced by a test for the 12 month period ending 31 July 2016. This deferral allows further time to agree amendments to Premier's medium term covenant profile and the resetting of its debt maturities. In return for the proposed amendments, it is anticipated that additional security will be provided for existing debt holders.

Premier expects negotiations to conclude during Q3 2016. Further deferral of the covenant test date will be sought if required.

Premier continues to have access to undrawn funds within its Revolving Credit Facility (RCF) to allow the company to meet its ongoing funding requirements.

Enquiries

 

 

Premier Oil plc

Tel: 020 7730 1111

Tony Durrant, Chief Executive

 

Richard Rose, Finance Director

 

 

Bell Pottinger

Tel: 020 3772 2570

Gavin Davis

 

Henry Lerwill

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFMMATMBIJBAF
Date   Source Headline
27th Mar 20175:59 pmRNSDirector/PDMR Shareholding
24th Mar 20172:00 pmRNSHolding(s) in Company
23rd Mar 20177:00 amRNSRevised conversion price for convertible bonds
15th Mar 20177:00 amRNSRefinancing update
14th Mar 20172:00 pmRNSHolding(s) in Company
9th Mar 20177:01 amRNSFinal Results
9th Mar 20177:00 amRNSRefinancing update
3rd Mar 20173:00 pmRNSHolding(s) in Company
3rd Mar 20179:00 amRNSHolding(s) in Company
2nd Mar 20175:00 pmRNSDirector/PDMR Shareholding
2nd Mar 20175:00 pmRNSHolding(s) in Company
2nd Mar 20173:00 pmRNSHolding(s) in Company
1st Mar 20174:30 pmRNSHolding(s) in Company
1st Mar 20177:00 amRNSRefinancing update
24th Feb 20172:28 pmRNSShare price weakness
3rd Feb 20177:00 amRNSAnnouncement of the proposed refinancing
2nd Feb 20175:00 pmRNSDirector/PDMR Shareholding
1st Feb 20177:00 amRNSDeferral of Financial Covenant Test
12th Jan 201712:00 pmRNSHolding(s) in Company
12th Jan 20177:00 amRNSTrading and Operations Update
5th Jan 201712:00 pmRNSDirector/PDMR Shareholding
3rd Jan 201712:00 pmRNSHolding(s) in Company
3rd Jan 201712:00 pmRNSBlock listing Interim Review
29th Dec 20167:00 amRNSDeferral of Financial Covenant Test
15th Dec 20165:10 pmRNSHolding(s) in Company
15th Dec 201612:00 pmRNSHolding(s) in Company
2nd Dec 20163:00 pmRNSDirector/PDMR Shareholding
2nd Dec 20169:00 amRNSTotal Voting Rights
30th Nov 20167:00 amRNSDeferral of Financial Covenant Test
18th Nov 201610:00 amRNSNotification of Change of Auditor
17th Nov 20167:00 amRNSTrading and Operations Update
14th Nov 201612:32 pmRNSTR-1: Notification of Interest
8th Nov 20161:01 pmRNSMarket speculation
8th Nov 201611:00 amRNSHolding(s) in Company
2nd Nov 201612:00 pmRNSDirector/PDMR Shareholding
1st Nov 20167:00 amRNSDeferral of Financial Covenant Test
24th Oct 20164:00 pmRNSHolding(s) in Company
21st Oct 20162:00 pmRNSHolding(s) in Company
4th Oct 20163:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20169:00 amRNSTotal Voting Rights
3rd Oct 20167:00 amRNSDeferral of financial covenant test
2nd Sep 20163:00 pmRNSDirector/PDMR Shareholding
2nd Sep 20163:00 pmRNSHolding(s) in Company
1st Sep 20167:00 amRNSLender Discussions Update
19th Aug 201612:34 pmRNSCorrection: Half-year Report
18th Aug 20167:00 amRNSHalf-year Report
17th Aug 201610:00 amRNSHolding(s) in Company
5th Aug 20165:00 pmRNSHolding(s) in Company
5th Aug 20167:00 amRNSBagpuss well result
3rd Aug 20165:19 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.